immunotherapy / GutMicro Cancer Research Results

immuno, immunotherapy: Click to Expand ⟱
Features: 
Immunotherapy is not one drug class. It includes:
-Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4)
-CAR-T therapies
-Monoclonal antibodies
-Cytokine therapies (IL-2, IFN-α)
-Cancer vaccines
-Bispecific T-cell engagers
PD-1 blockade antibody therapy is one of the cornerstone approaches in modern cancer immunotherapy.
Under normal physiological conditions, when PD-1 binds to its ligands (PD-L1 or PD-L2) on other cells, it functions as a "checkpoint" to reduce overly active T cell responses and prevent autoimmunity.
PD-1 blockade therapies involve monoclonal antibodies that target either PD-1 or its ligand PD-L1.
• By blocking the interaction between PD-1 and its ligands, these antibodies effectively release the "brakes" on T cells.
• The re-activated T cells can then recognize and destroy cancer cells more efficiently.

Immunotherapy Class Example Agents Primary Target Core Mechanism Interaction Considerations Net Effect
PD-1 inhibitors Nivolumab, Pembrolizumab PD-1 receptor on T cells Blocks inhibitory PD-1 signaling → restores cytotoxic T-cell activity High-dose steroids or strong immunosuppressants may blunt effect; autoimmune risk ↑ Anti-tumor immune activation
PD-L1 inhibitors Atezolizumab, Durvalumab PD-L1 on tumor/immune cells Prevents PD-L1 from engaging PD-1 → enhances T-cell response Similar immune-related adverse event (irAE) profile as PD-1 inhibitors ↑ Immune activation
CTLA-4 inhibitors Ipilimumab CTLA-4 checkpoint Enhances early T-cell priming in lymph nodes Higher autoimmune toxicity risk vs PD-1 class ↑ T-cell priming
CAR-T therapy CD19 CAR-T products Tumor antigen (e.g., CD19) Genetically engineered T cells directly target tumor cells Risk of cytokine release syndrome (CRS) and neurotoxicity Direct immune-mediated tumor killing
Monoclonal antibodies (non-checkpoint) Trastuzumab, Rituximab Specific tumor antigens Antibody-dependent cellular cytotoxicity (ADCC) or receptor blockade Combination with chemo common; immune activation depends on Fc engagement Targeted immune-mediated killing
Cytokine therapy IL-2, IFN-α Immune activation pathways Stimulates T-cell and NK cell proliferation High systemic toxicity; rarely used now vs checkpoint inhibitors Broad immune stimulation
Cancer vaccines mRNA or peptide-based Tumor antigens Induces tumor-specific immune memory Often combined with checkpoint blockade Adaptive immune priming
Bispecific T-cell engagers Blinatumomab CD3 + tumor antigen Bridges T cells directly to tumor cells CRS risk; continuous infusion in some protocols Direct T-cell redirection


GutMicro, Gut Microbiota: Click to Expand ⟱
Source:
Type:
Gut microbiome may affect responses to numerous forms of cancer therapy.
The gut microbiota plays a multifaceted role in cancer biology, influencing tumor development, progression, and patient prognosis. Dysbiosis and specific microbial populations have been linked to various cancers, with implications for patient outcomes. While the relationship between gut microbiota and cancer prognosis is an active area of research, it holds promise for the development of microbiome-based biomarkers and therapeutic strategies in oncology.


Scientific Papers found: Click to Expand⟱
1161- ACNs,  immuno,    Bilberry anthocyanin extracts enhance anti-PD-L1 efficiency by modulating gut microbiota
- in-vivo, Colon, MC38
GutMicro↑,
5571- B-Gluc,  immuno,    Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review
- Review, Var, NA
Imm↑, ChemoSen↑, LDL↑, GutMicro↑, TumCP↓, Apoptosis↑, angioG↓, QoL↑,
5628- Bif,  immuno,    Bifidobacterium modulation of tumor immunotherapy and its mechanism
- Review, Var, NA
Imm↑, Risk↓, GutMicro↑, AntiTum↑, OS↑, selectivity↑, eff↑,
5621- Bif,  immuno,    Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
TumCG↓, GutMicro↑,
1856- dietFMD,  immuno,    Targeting the Gut Microbiome to Improve Immunotherapy Outcomes: A Review
- Review, Var, NA
GutMicro↑,
1038- F,  immuno,    Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota.
- in-vivo, BC, NA
GutMicro↑, T-Cell↑, Treg lymp↓,
1046- ProBio,  immuno,    Combination Therapy of Bifidobacterium longum RAPO With Anti-PD-1 Treatment Enhances Anti-tumor Immune Response in Association With Gut Microbiota Modulation
- in-vivo, NA, NA
TumVol↓, GutMicro↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

LDL↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Migration ⓘ

Treg lymp↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,  

Immune & Inflammatory Signaling ⓘ

Imm↑, 2,   T-Cell↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 7,  

Functional Outcomes ⓘ

AntiTum↑, 1,   OS↑, 1,   QoL↑, 1,   Risk↓, 1,   TumVol↓, 1,  
Total Targets: 17

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: GutMicro, Gut Microbiota
7 immunotherapy
2 Bifidobacterium
1 Anthocyanins
1 beta-glucans
1 diet FMD Fasting Mimicking Diet
1 Fucoidan
1 probiotics
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:207  Target#:350  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page